nach oben

Erschienen in:

06.07.2018 | Original Article

Attention-deficit hyperactivity disorder in Brazilian patients with phenylketonuria

verfasst von: Fernanda Gabriel Santos da Silva, Filippo Pinto e Vairo, Carolina Fischinger Moura de Souza, Ida Vanessa Doederlein Schwartz

Erschienen in: Acta Neurologica Belgica | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Recent studies have shown that patients with phenylketonuria (PKU), even with the early diagnosis and continuous treatment, may have symptoms of attention-deficit hyperactivity disorder (ADHD) and that the prevalence of ADHD in this population would be higher than in the general population. This study aims to determine the prevalence of ADHD in a sample of PKU patients from Southern Brazil. Patients were prospectively assessed by clinical interviews, neurological examination, and application of the MTA-SNAP-IV scales for patients aged 5–17 years and the Adult Self-Report Scale for patients over 17 years. Thirty-one patients (mean age = 17.4; early diagnosis = 27) were followed. Patients with ADHD and younger than 17 years had a median Phe in the last 6 months of life higher than those without the diagnosis of ADHD (ADHD patients = 617.1 µmol/L, no-ADHD patients 393.2 µmol/L, and p = 0.03). There was a predominantly hyperactive/impulsivity clinical presentation of ADHD (n = 4/5 patients), which differs from that reported elsewhere in the literature. Future studies are essential to better define the clinical presentation of ADHD in these patients and further elucidate its pathophysiology.

Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376:1417–1427. https://doi.org/10.1016/S0140-6736(10)60961-0 CrossRefPubMed

van Wegberg AMJ, MacDonald A, Ahring K et al (2017) The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 12:162. https://doi.org/10.1186/s13023-017-0685-2 CrossRefPubMedPubMedCentral

van Spronsen FJ, van Wegberg AM, Ahring K et al (2017) Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 8587:1–14. https://doi.org/10.1016/S2213-8587(16)30320-5 CrossRef

Vockley J, Andersson HC, Antshel KM et al (2014) Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 16:188–200. https://doi.org/10.1038/gim.2013.157 CrossRefPubMed

Ney DM, Stroup BM, Clayton MK et al (2016) Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial. Am J Clin Nutr 104:334–345. https://doi.org/10.3945/ajcn.116.135293 CrossRefPubMedPubMedCentral

Zaki OK, El-Wakeel L, Ebeid Y et al (2016) The use of glycomacropeptide in dietary management of phenylketonuria. J Nutr Metab 2016:1–5. https://doi.org/10.1155/2016/2453027 CrossRef

Concolino D, Mascaro I, Moricca MT et al (2017) Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids. Eur J Clin Nutr 71:51–55. https://doi.org/10.1038/ejcn.2016.166 CrossRefPubMed

Williams RA, Mamotte CDS, Burnett JR (2008) Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev 29:31–41PubMedPubMedCentral

Al Hafid N, Christodoulou J (2015) Phenylketonuria: a review of current and future treatments. Transl Pediatr 4:304–317. https://doi.org/10.3978/j.issn.2224-4336.2015.10.07 CrossRefPubMedPubMedCentral

10.

Stevenson M, McNaughton N (2013) A comparison of phenylketonuria with attention deficit hyperactivity disorder: do markedly different aetiologies deliver common phenotypes? Brain Res Bull 99:63–83. https://doi.org/10.1016/j.brainresbull.2013.10.003 CrossRefPubMed

11.

Moyle JJ, Fox AM, Arthur M et al (2007) Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev 17:91–101. https://doi.org/10.1007/s11065-007-9021-2 CrossRefPubMed

12.

Brumm VL, Bilder D, Waisbren SE (2010) Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 99:S59–S63. https://doi.org/10.1016/j.ymgme.2009.10.182 CrossRefPubMed

13.

Saad K, Elserogy Y, Abdel rahman AA et al (2015) ADHD, autism and neuroradiological complications among phenylketonuric children in Upper Egypt. Acta Neurol Belg 115:657–663. https://doi.org/10.1007/s13760-014-0422-8 CrossRefPubMed

14.

Antshel KM (2010) ADHD, learning, and academic performance in phenylketonuria. Mol Genet Metab 99:S52–S58. https://doi.org/10.1016/j.ymgme.2009.09.013 CrossRefPubMed

15.

Antshell KM, Waisbren SE (2003) Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J Abnorm Child Psychol 31:565–574. https://doi.org/10.1023/A:1026239921561 CrossRef

16.

Baker GB, Bornstein RA, Rouget AC et al (1991) Phenylethylaminergic mechanisms in attention-deficit disorder. Biol Psychiatry 29:15–22. https://doi.org/10.1016/0006-3223(91)90207-3 CrossRefPubMed

17.

Arnsten AFT (2006) Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 67:7–12CrossRef

18.

Landvogt C, Mengel E, Bartenstein P et al (2008) Reduced cerebral fluoro-l-dopamine uptake in adult patients suffering from phenylketonuria. J Cereb Blood Flow Metab 28:824–831. https://doi.org/10.1038/sj.jcbfm.9600571 CrossRefPubMed

19.

Arnold GL, Vladutiu CJ, Orlowski CC et al (2004) Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 27:137–143. https://doi.org/10.1023/B:BOLI.0000028725.37345.62 CrossRefPubMed

20.

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th ed. American Psychiatric Association, Arlington, VACrossRef

21.

Mattos P, Serra-Pinheiro MA, Rohde LA, Pinto D (2006) Apresentação de uma versão em português para uso no Brasil do instrumento MTA-SNAP-IV de avaliação de sintomas de transtorno do déficit de atenção/hiperatividade e sintomas de transtorno desafiador e de oposição. Rev Psiquiatr do Rio Gd do Sul 28:290–297. https://doi.org/10.1590/S0101-81082006000300008 CrossRef

22.

Mattos P, Segenreich D, Saboya E et al (2006) Adaptação transcultural para o português da escala Adult Self-Report Scale para avaliação do transtorno de déficit de atenção/hiperatividade (TDAH) em adultos. Rev Psiquiatr Clin 33:188–194. https://doi.org/10.1590/S0101-60832006000400004 CrossRef

23.

Kessler RC, Adler L, Ames M et al (2005) The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med 35:245–256. https://doi.org/10.1017/S0033291704002892 CrossRefPubMed

24.

Feillet F, van Spronsen FJ, MacDonald A et al (2010) Challenges and pitfalls in the management of phenylketonuria. Pediatrics 126:333–341. https://doi.org/10.1542/peds.2009-3584 CrossRefPubMed

25.

Rohde LA, Biederman J, Busnello EA et al (1999) ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. J Am Acad Child Adolesc Psychiatry 38:716–722. https://doi.org/10.1097/00004583-199906000-00019 CrossRefPubMed

26.

Polanczyk G, Laranjeira R, Zaleski M et al (2010) ADHD in a representative sample of the Brazilian population: estimated prevalence and comparative adequacy of criteria between adolescents and adults according to the item response theory. Int J Methods Psychiatr Res 19:177–184. https://doi.org/10.1002/mpr.319 CrossRefPubMedPubMedCentral

27.

Burton B, Grant M, Feigenbaum A et al (2015) A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. Mol Genet Metab 114:415–424. https://doi.org/10.1016/j.ymgme.2014.11.011 CrossRefPubMed

28.

Huijbregts SCJ, De Sonneville LMJ, Licht R et al (2002) Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 40:7–15. https://doi.org/10.1016/S0028-3932(01)00078-1 CrossRefPubMed

29.

Wyrwich KW, Auguste P, Yu R et al (2015) Evaluation of neuropsychiatric function in phenylketonuria: psychometric properties of the ADHD Rating Scale-IV and Adult ADHD Self-Report Scale inattention subscale in phenylketonuria. Value Health 18:404–412. https://doi.org/10.1016/j.jval.2015.01.008 CrossRefPubMed

30.

Weglage J, Pietsch M, Fünders B et al (1996) Deficits in selective and sustained attention processes in early treated children with phenylketonuria—result of impaired frontal lobe functions? Eur J Pediatr 155:200–204. https://doi.org/10.1007/BF01953938 CrossRefPubMed

31.

Christ SE, Huijbregts SCJ, de Sonneville LMJ, White DA (2009) Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab 99:S22–S32. https://doi.org/10.1016/j.ymgme.2009.10.007 CrossRef

32.

Bilder DA, Noel JK, Baker ER et al (2016) Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria. Dev Neuropsychol 41:245–260. https://doi.org/10.1080/87565641.2016.1243109 CrossRefPubMedPubMedCentral

33.

de Carvalho TM, dos Santos HP, dos Santos ICGP et al (2007) Newborn screening: a national public health programme in Brazil. J Inherit Metab Dis 30:615. https://doi.org/10.1007/s10545-007-0650-7 CrossRefPubMed

34.

Anderson PJ, Leuzzi V (2010) White matter pathology in phenylketonuria. Mol Genet Metab 99:S3–S9. https://doi.org/10.1016/j.ymgme.2009.10.005 CrossRefPubMed

35.

Anderson PJ, Wood SJ, Francis DE et al (2004) Neuropsychological functioning in children with early-treated phenylketonuria: impact of white matter abnormalities. Dev Med Child Neurol 46:230–238. https://doi.org/10.1017/S0012162204000386 CrossRefPubMed

36.

Cleary MA, Walter JH, Wraith JE et al (1994) Magnetic resonance imaging of the brain in phenylketonuria. Lancet 344:87–90CrossRef

37.

Mastrangelo M, Chiarotti F, Berillo L et al (2015) The outcome of white matter abnormalities in early treated phenylketonuric patients: a retrospective longitudinal long-term study. Mol Genet Metab 116:171–177. https://doi.org/10.1016/j.ymgme.2015.08.005 CrossRefPubMed

38.

White DA, Antenor-Dorsey JAV, Grange DK et al (2013) White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH₄) in individuals with phenylketonuria. Mol Genet Metab 110:1–15. https://doi.org/10.1016/j.ymgme.2013.07.010 CrossRef

Titel: Attention-deficit hyperactivity disorder in Brazilian patients with phenylketonuria
verfasst von: Fernanda Gabriel Santos da Silva
Filippo Pinto e Vairo
Carolina Fischinger Moura de Souza
Ida Vanessa Doederlein Schwartz
Publikationsdatum: 06.07.2018
Verlag: Springer International Publishing
Erschienen in: Acta Neurologica Belgica / Ausgabe 4/2020
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-018-0972-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Attention-deficit hyperactivity disorder in Brazilian patients with phenylketonuria

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

The fusiform gyrus and theory of mind: a case study

Relationship between MIDAS, depression, anxiety and alexithymia in migraine patients

Yap-Hippo pathway regulates cerebral hypoxia-reoxygenation injury in neuroblastoma N2a cells via inhibiting ROCK1/F-actin/mitochondrial fission pathways

Ruptured de novo posterior inferior cerebellar artery aneurysm associated with fibromuscular dysplasia

Erythropoietin-induced cluster of seizures in two children with cerebral palsy

Eine Komplikation der COVID-19-Erkrankung: Delir

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie